Trade Basilea Pharma AG - BSLN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 1.35 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.015699% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.006523% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | CHF | ||||||||
Margin | 5% | ||||||||
Stock exchange | Switzerland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Basilea Pharmaceutica AG Allschwil ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 40 |
Open* | 40.05 |
1-Year Change* | -2.55% |
Day's Range* | 40 - 40.75 |
52 wk Range | 36.80-55.40 |
Average Volume (10 days) | 20.90K |
Average Volume (3 months) | 502.88K |
Market Cap | 619.62M |
P/E Ratio | 10.05 |
Shares Outstanding | 11.98M |
Revenue | 174.02M |
EPS | 4.71 |
Dividend (Yield %) | N/A |
Beta | 1.26 |
Next Earnings Date | Feb 12, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 3, 2023 | 40.00 | -1.40 | -3.38% | 41.40 | 41.80 | 40.00 |
Oct 2, 2023 | 41.65 | -0.05 | -0.12% | 41.70 | 42.25 | 41.10 |
Sep 29, 2023 | 40.00 | -0.65 | -1.60% | 40.65 | 41.55 | 40.00 |
Sep 28, 2023 | 40.80 | -0.55 | -1.33% | 41.35 | 41.40 | 40.40 |
Sep 27, 2023 | 40.95 | 0.80 | 1.99% | 40.15 | 41.10 | 40.15 |
Sep 26, 2023 | 40.45 | -1.25 | -3.00% | 41.70 | 41.90 | 40.45 |
Sep 25, 2023 | 41.45 | -0.80 | -1.89% | 42.25 | 42.50 | 41.15 |
Sep 22, 2023 | 42.40 | 0.20 | 0.47% | 42.20 | 42.95 | 42.15 |
Sep 21, 2023 | 42.80 | -0.15 | -0.35% | 42.95 | 43.60 | 42.75 |
Sep 20, 2023 | 43.40 | -0.05 | -0.12% | 43.45 | 43.65 | 42.90 |
Sep 19, 2023 | 43.15 | -0.45 | -1.03% | 43.60 | 44.75 | 43.15 |
Sep 18, 2023 | 43.80 | -1.10 | -2.45% | 44.90 | 44.95 | 43.45 |
Sep 15, 2023 | 45.15 | -0.20 | -0.44% | 45.35 | 45.65 | 44.60 |
Sep 14, 2023 | 44.80 | -1.45 | -3.14% | 46.25 | 46.85 | 44.80 |
Sep 13, 2023 | 46.05 | 1.00 | 2.22% | 45.05 | 47.55 | 44.70 |
Sep 12, 2023 | 47.45 | 0.60 | 1.28% | 46.85 | 47.65 | 46.45 |
Sep 11, 2023 | 46.90 | -0.25 | -0.53% | 47.15 | 48.30 | 46.90 |
Sep 8, 2023 | 47.85 | 0.90 | 1.92% | 46.95 | 48.00 | 46.70 |
Sep 7, 2023 | 46.35 | 0.05 | 0.11% | 46.30 | 47.20 | 46.30 |
Sep 6, 2023 | 47.25 | 0.85 | 1.83% | 46.40 | 47.30 | 45.75 |
Basilea Pharma AG Events
Time (UTC) | Country | Event |
---|---|---|
Monday, February 12, 2024 | ||
Time (UTC) 07:30 | Country CH
| Event Full Year 2023 Basilea Pharmaceutica AG Earnings Release Full Year 2023 Basilea Pharmaceutica AG Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 147.765 | 148.122 | 127.629 | 134.381 | 132.555 |
Revenue | 147.765 | 148.122 | 127.629 | 134.381 | 132.555 |
Cost of Revenue, Total | 24.603 | 24.072 | 24.054 | 18.868 | 20.299 |
Gross Profit | 123.162 | 124.05 | 103.575 | 115.513 | 112.256 |
Total Operating Expense | 129.263 | 147.432 | 136.165 | 151.581 | 156.65 |
Selling/General/Admin. Expenses, Total | 30.815 | 29.721 | 29.422 | 30.051 | 31.409 |
Research & Development | 73.804 | 93.157 | 97.41 | 102.662 | 104.942 |
Operating Income | 18.502 | 0.69 | -8.536 | -17.2 | -24.095 |
Interest Income (Expense), Net Non-Operating | -9.522 | -8.085 | -7.485 | -6.396 | -6.528 |
Other, Net | 3.122 | 0.601 | 1.354 | 1.214 | -0.537 |
Net Income Before Taxes | 12.102 | -6.794 | -14.667 | -22.382 | -31.16 |
Net Income After Taxes | 12.147 | -6.831 | -14.722 | -22.422 | -31.352 |
Net Income Before Extra. Items | 12.147 | -6.831 | -14.722 | -22.422 | -31.352 |
Net Income | 12.147 | -6.831 | -14.722 | -22.422 | -31.352 |
Income Available to Common Excl. Extra. Items | 12.147 | -6.831 | -14.722 | -22.422 | -31.352 |
Income Available to Common Incl. Extra. Items | 12.147 | -6.831 | -14.722 | -22.422 | -31.352 |
Diluted Net Income | 12.147 | -6.831 | -14.722 | -22.422 | -31.352 |
Diluted Weighted Average Shares | 11.861 | 11.682 | 10.2815 | 10.7557 | 10.8379 |
Diluted EPS Excluding Extraordinary Items | 1.02412 | -0.58475 | -1.43189 | -2.08466 | -2.89281 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | 1.02636 | -0.55793 | -2.36256 | -2.08466 | -2.89281 |
Unusual Expense (Income) | 0.041 | 0.482 | -14.721 | ||
Other Operating Expenses, Total | 0 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total revenue | 84.905 | 89.118 | 57.647 | 93.924 | 54.198 |
Revenue | 84.905 | 89.118 | 57.647 | 93.924 | 54.198 |
Cost of Revenue, Total | 9.996 | 9.684 | 14.919 | 10.547 | 13.525 |
Gross Profit | 74.909 | 79.434 | 42.728 | 83.377 | 40.673 |
Total Operating Expense | 48.007 | 61.531 | 67.732 | 77.624 | 69.808 |
Selling/General/Admin. Expenses, Total | 16.544 | 15.194 | 15.621 | 15.382 | 14.339 |
Research & Development | 21.467 | 36.656 | 37.148 | 51.468 | 41.689 |
Operating Income | 36.898 | 27.587 | -10.085 | 16.3 | -15.61 |
Interest Income (Expense), Net Non-Operating | -5.307 | -5.773 | -3.749 | -4.01 | -4.075 |
Other, Net | 0.276 | 2.509 | 1.613 | 0.793 | -0.192 |
Net Income Before Taxes | 31.867 | 24.323 | -12.221 | 13.083 | -19.877 |
Net Income After Taxes | 31.84 | 24.356 | -12.209 | 13.06 | -19.891 |
Net Income Before Extra. Items | 31.84 | 24.356 | -12.209 | 13.06 | -19.891 |
Net Income | 31.84 | 24.356 | -12.209 | 13.06 | -19.891 |
Income Available to Common Excl. Extra. Items | 31.84 | 24.356 | -12.209 | 13.06 | -19.891 |
Income Available to Common Incl. Extra. Items | 31.84 | 24.356 | -12.209 | 13.06 | -19.891 |
Diluted Net Income | 31.84 | 24.356 | -12.209 | 13.06 | -19.891 |
Diluted Weighted Average Shares | 11.9781 | 11.8828 | 11.8391 | 11.7986 | 11.5653 |
Diluted EPS Excluding Extraordinary Items | 2.65818 | 2.04969 | -1.03124 | 1.10691 | -1.71988 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | 2.65818 | 2.04952 | -1.02883 | 1.12612 | -1.70555 |
Unusual Expense (Income) | 0 | -0.003 | 0.044 | 0.227 | 0.255 |
Other Operating Expenses, Total | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 175.364 | 241.066 | 223.528 | 184.86 | 274.738 |
Cash and Short Term Investments | 84.659 | 148.7 | 161.772 | 129.024 | 223.034 |
Cash | 34.7 | 53.7 | 50.1 | 52.5 | 37.4 |
Cash & Equivalents | 49.959 | 0 | 10.649 | 56.524 | 135.634 |
Short Term Investments | 0 | 95 | 101.023 | 20 | 50 |
Total Receivables, Net | 63.612 | 65.7 | 37.901 | 30.315 | 35.593 |
Accounts Receivable - Trade, Net | 33.152 | 8.71 | 6.242 | 3.757 | |
Total Inventory | 24.244 | 22.783 | 21.192 | 18.569 | 14.411 |
Other Current Assets, Total | 2.849 | 3.883 | 2.663 | 6.952 | 1.7 |
Total Assets | 220.848 | 247.267 | 229.794 | 221.467 | 281.751 |
Property/Plant/Equipment, Total - Net | 21.571 | 2.923 | 5.275 | 5.162 | 6.424 |
Property/Plant/Equipment, Total - Gross | 30.294 | 17.505 | 29.348 | 44.2 | 45 |
Accumulated Depreciation, Total | -10.3 | -14.6 | -24.1 | -39 | -38.6 |
Intangibles, Net | 0.578 | 0.632 | 0.672 | 0.372 | 0.372 |
Long Term Investments | 0 | 30 | 0 | ||
Other Long Term Assets, Total | 22.069 | 0.256 | 0.319 | 1.073 | 0.217 |
Total Current Liabilities | 74.85 | 174.408 | 50.161 | 75.494 | 66.684 |
Accounts Payable | 0.191 | 10.617 | 13.151 | 6.765 | 6.399 |
Accrued Expenses | 27.859 | 33.453 | 29.052 | 29.3 | 26.7 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 9.333 | 6.833 | 7.958 | 39.429 | 33.585 |
Total Liabilities | 241.563 | 305.874 | 331.84 | 314.427 | 348.438 |
Total Long Term Debt | 131.36 | 94.544 | 239.668 | 197.74 | 196.982 |
Long Term Debt | 131.36 | 94.544 | 239.668 | 197.74 | 196.982 |
Other Liabilities, Total | 35.353 | 36.922 | 42.011 | 41.193 | 84.772 |
Total Equity | -20.715 | -58.607 | -102.046 | -92.96 | -66.687 |
Common Stock | 13.093 | 12.992 | 11.922 | 11.882 | 11.879 |
Retained Earnings (Accumulated Deficit) | 26.048 | 6.577 | -33.95 | -74.324 | -55.05 |
Treasury Stock - Common | -56.071 | -56.559 | -52.766 | -5.963 | -7.235 |
Other Equity, Total | -3.785 | -21.617 | -27.252 | -24.555 | -16.281 |
Total Liabilities & Shareholders’ Equity | 220.848 | 247.267 | 229.794 | 221.467 | 281.751 |
Total Common Shares Outstanding | 11.9513 | 11.842 | 10.8673 | 10.7739 | 10.7447 |
Note Receivable - Long Term | 1.266 | 2.39 | |||
Current Port. of LT Debt/Capital Leases | 37.467 | 123.505 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Dec 2020 | |
---|---|---|---|---|---|
Total Current Assets | 175.364 | 211.789 | 241.066 | 220.189 | 223.528 |
Cash and Short Term Investments | 84.659 | 140.736 | 148.7 | 162.849 | 161.772 |
Cash & Equivalents | 84.659 | 45.746 | 53.7 | 82.849 | 60.749 |
Short Term Investments | 0 | 94.99 | 95 | 80 | 101.023 |
Total Receivables, Net | 63.612 | 39.72 | 65.7 | 31.264 | 37.901 |
Accounts Receivable - Trade, Net | 33.152 | 10.946 | 6.618 | 8.71 | |
Total Inventory | 24.244 | 24.754 | 22.783 | 20.94 | 21.192 |
Other Current Assets, Total | 2.849 | 6.579 | 3.883 | 5.136 | 2.663 |
Total Assets | 220.848 | 236.073 | 247.267 | 227.176 | 229.794 |
Property/Plant/Equipment, Total - Net | 21.571 | 21.619 | 2.923 | 3.767 | 5.275 |
Property/Plant/Equipment, Total - Gross | 30.294 | 36.044 | 17.505 | 20.772 | 29.348 |
Accumulated Depreciation, Total | -10.3 | -14.4 | -14.6 | -17 | -24.1 |
Intangibles, Net | 0.578 | 1.247 | 0.632 | 0.467 | 0.672 |
Long Term Investments | 0 | ||||
Other Long Term Assets, Total | 22.069 | 0.152 | 0.256 | 0.363 | 0.319 |
Total Current Liabilities | 74.85 | 155.443 | 174.408 | 37.707 | 50.161 |
Accounts Payable | 0.191 | 4.706 | 10.617 | 5.378 | 13.151 |
Accrued Expenses | 27.859 | 23.709 | 33.453 | 25.235 | 29.052 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 9.333 | 9.833 | 6.833 | 7.094 | 7.958 |
Total Liabilities | 241.563 | 303.239 | 305.874 | 305.928 | 331.84 |
Total Long Term Debt | 131.36 | 94.77 | 94.544 | 227.869 | 239.668 |
Long Term Debt | 131.36 | 94.77 | 94.544 | 227.869 | 239.668 |
Other Liabilities, Total | 35.353 | 53.026 | 36.922 | 40.352 | 42.011 |
Total Equity | -20.715 | -67.166 | -58.607 | -78.752 | -102.046 |
Common Stock | 13.093 | 12.999 | 12.992 | 12.931 | 11.922 |
Retained Earnings (Accumulated Deficit) | 26.048 | -3.794 | 6.577 | -10.401 | -33.95 |
Treasury Stock - Common | -56.071 | -55.865 | -56.559 | -56.309 | -52.766 |
Other Equity, Total | -3.785 | -20.506 | -21.617 | -24.973 | -27.252 |
Total Liabilities & Shareholders’ Equity | 220.848 | 236.073 | 247.267 | 227.176 | 229.794 |
Total Common Shares Outstanding | 11.9513 | 11.8512 | 11.842 | 11.7932 | 10.8673 |
Current Port. of LT Debt/Capital Leases | 37.467 | 117.195 | 123.505 | ||
Note Receivable - Long Term | 1.266 | 1.266 | 2.39 | 2.39 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 12.147 | -6.831 | -14.722 | -22.422 | -31.352 |
Cash From Operating Activities | 7.056 | -32.02 | -54.134 | -63.836 | -79.21 |
Cash From Operating Activities | 1.097 | 0.754 | 1.19 | 1.639 | 1.852 |
Non-Cash Items | 4.095 | 5.844 | -9.84 | 3.806 | 7.009 |
Changes in Working Capital | -10.283 | -31.787 | -30.762 | -46.859 | -56.719 |
Cash From Investing Activities | 91.649 | 3.575 | -34.963 | -0.404 | 59.391 |
Capital Expenditures | -3.303 | -0.86 | -2.265 | -0.404 | -0.609 |
Other Investing Cash Flow Items, Total | 94.952 | 4.435 | -32.698 | 0 | 60 |
Cash From Financing Activities | -45.246 | 16.64 | 45.067 | 1.309 | -5.986 |
Issuance (Retirement) of Stock, Net | 4.426 | 39.852 | 4.809 | 1.309 | -5.986 |
Issuance (Retirement) of Debt, Net | -49.672 | -23.212 | 43.451 | ||
Foreign Exchange Effects | 0.155 | 0.501 | -0.758 | 0.067 | -1.011 |
Net Change in Cash | 53.614 | -11.304 | -44.788 | -62.864 | -26.816 |
Cash Taxes Paid | 0.004 | 0.035 | 0.026 | 0.141 | 0.413 |
Cash Interest Paid | 6.334 | 7.074 | 4.843 | 5.666 | 5.795 |
Financing Cash Flow Items | -3.193 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Dec 2020 | |
---|---|---|---|---|---|
Net income/Starting Line | 12.147 | -12.209 | -6.831 | -19.891 | -14.722 |
Cash From Operating Activities | 7.056 | 0.149 | -32.02 | -27.151 | -54.134 |
Cash From Operating Activities | 1.097 | 0.357 | 0.754 | 0.399 | 1.19 |
Non-Cash Items | 4.095 | 2.36 | 5.844 | 2.705 | -9.84 |
Changes in Working Capital | -10.283 | 9.641 | -31.787 | -10.364 | -30.762 |
Cash From Investing Activities | 91.649 | -2.319 | 3.575 | 19.113 | -34.963 |
Capital Expenditures | -3.303 | -2.329 | -0.86 | -0.307 | -2.265 |
Other Investing Cash Flow Items, Total | 94.952 | 0.01 | 4.435 | 19.42 | -32.698 |
Cash From Financing Activities | -45.246 | -6.764 | 16.64 | 26.195 | 45.067 |
Issuance (Retirement) of Stock, Net | 4.426 | -0.165 | 39.852 | 38.82 | 4.809 |
Foreign Exchange Effects | 0.155 | 0.841 | 0.501 | 0.249 | -0.758 |
Net Change in Cash | 53.614 | -8.093 | -11.304 | 18.406 | -44.788 |
Financing Cash Flow Items | -3.193 | ||||
Issuance (Retirement) of Debt, Net | -49.672 | -6.599 | -23.212 | -12.625 | 43.451 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Black Creek Investment Management, Inc. | Investment Advisor | 5.0663 | 663670 | 25430 | 2023-05-08 | LOW |
CI Global Asset Management | Investment Advisor/Hedge Fund | 4.8722 | 638240 | 4613 | 2022-12-31 | MED |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 3.2548 | 426360 | -369 | 2022-12-31 | LOW |
Family (Braginsky) | Other Insider Investor | 3.0067 | 393863 | 5928 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.7043 | 354254 | 2358 | 2023-07-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.4333 | 318750 | 153618 | 2022-11-29 | LOW |
Zürcher Kantonalbank (Asset Management) | Bank and Trust | 2.4288 | 318169 | -13081 | 2023-06-30 | LOW |
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH | Investment Advisor | 2.3711 | 310600 | 0 | 2023-06-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.0768 | 272047 | 272047 | 2022-12-31 | LOW |
UBS Asset Management (Switzerland) | Investment Advisor | 1.0368 | 135818 | -1154 | 2023-07-31 | LOW |
JPMorgan Chase & Co | Holding Company | 1.0318 | 135155 | -267417 | 2023-03-22 | HIGH |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.8234 | 107866 | 0 | 2023-07-31 | LOW |
Saint Olive Gestion | Investment Advisor | 0.5344 | 70000 | 0 | 2022-12-31 | LOW |
Bank J. Safra Sarasin AG (Asset Management) | Bank and Trust | 0.515 | 67464 | -5901 | 2023-06-30 | MED |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4538 | 59446 | 0 | 2023-07-31 | LOW |
California State Teachers Retirement System | Pension Fund | 0.3755 | 49183 | 723 | 2022-06-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 0.2626 | 34404 | 1018 | 2023-04-30 | LOW |
Deka Investment GmbH | Investment Advisor/Hedge Fund | 0.2523 | 33056 | -3500 | 2022-12-31 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.2484 | 32542 | 0 | 2023-04-30 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.2322 | 30417 | 190 | 2023-07-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Basilea Company profile
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
Hegenheimermattweg 167b
ALLSCHWIL
BASEL-LANDSCHAFT 4123
CH
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com